Retrospective Analysis of Prognostic Factors in Patients with Small Cell Lung Cancer
Prognosis in Small Cell Lung Cancer
Abstract views: 122
/ 
PDF downloads: 68
DOI:
https://doi.org/10.5281/zenodo.7772698Keywords:
Small cell lung cancer, prognostic factors, survival, lung cancerAbstract
Background: The goal of this study is to examine how small cell lung cancer (SCLC) prognosis and survival are impacted by pre-treatment clinical characteristics and laboratory data.
Material and Method: The 118 patients diagnosed with SCLC in our center between August 2000 and December 2008 were evaluated retrospectively. The effects of the 19 variables [hemoglobin (Hgb), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), albumin, sedimentation, sodium (Na), neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA 15-3), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9), alpha-fetoprotein (AFP), performance status (PS), stage, sex, weight loss, age, smoking, chemotherapy (CT) related to the prognosis on survival were thoroughly investigated in detail. Statistically, univariate analyses were performed via Kaplan-Meier Method and multivariate analyses were performed via the Cox proportional hazards (Cox PH) model. The covariates that were found to have a significant relation (p<0.05) on prognosis in univariate analyses and the ones with p<0.15 in the univariate analyses were subjected to multivariate analysis to determine independent prognostic factors.
Results: In univariate analyses, albumin, Na, NSE, CA 125, stage, and sex had a significant relation to prognosis (p<0.05). In multivariate analyses, only the stage parameter was found to be an independent predictive factor on prognosis (p=0.019).
Conclusion: The knowledge of prognostic factors like the laboratory and clinical parameters and staging of the patients were considered to have a directing role in determining treatment strategies and clinical follow-up in SCLC.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Shy SW, Lee WH, Chou MC, Lai YS, Tu YC. Small cell lung carcinoma: clinicopathological, immunohistochemical, and ultrastructural study. J Surg Oncol. 1990;45(3):146-161. doi:10.1002/jso.2930450304
Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544. doi:10.1200/JCO.2005.04.4859
Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973;4(2):31-42.
Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993;329(25):1848-1852. doi:10.1056/NEJM199312163292504
Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89(9):1953-1960. doi:10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y
Hurria A, Kris MG. Management of lung cancer in older adults. CA Cancer J Clin. 2003;53(6):325-341. doi:10.3322/canjclin.53.6.325
Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523-533. doi:10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6
de Wet M, Falkson G, Rapoport BL. Small cell lung cancer: analysis of factors influencing the response to treatment and survival. Oncology. 1994;51(6):523-534. doi:10.1159/000227398
Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83(3):355-367. doi:10.4065/83.3.355
Ozlü T, Bülbül Y. Smoking and lung cancer. Tuberk Toraks. 2005;53(2):200-209.
Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research [published correction appears in Br J Cancer 1990 Sep;62(3):550]. Br J Cancer. 1990;61(4):597-604. doi:10.1038/bjc.1990.133
Dearing MP, Steinberg SM, Phelps R, et al. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 1990;8(6):1042-1049. doi:10.1200/JCO.1990.8.6.1042
Cohen MH, Makuch R, Johnston-Early A, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep. 1981;65(3-4):187-195.
Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer. 1998;82(6):1049-1055. doi:10.1002/(sici)1097-0142(19980315)82:6<1049::aid-cncr6>3.0.co;2-9
Sculier JP, Feld R, Evans WK, et al. Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol. 1985;3(10):1349-1354. doi:10.1200/JCO.1985.3.10.1349
Karlıkaya C, Erdoğan S, Akkoçlu A, vd. Akciğer kanserinde çoklu tümör belirleyicisi analizi, Toraks Dergisi. 2003;4(3):248-259.
Downloads
Published
How to Cite
License
Copyright (c) 2023 Journal of European Internal Medicine Professionals (JEIMP) e-ISSN: 2980-0617
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 